Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Amlodipine
Amlodipine- reference · 5 trials · 5 indications
Value at Week 8 minus value at baseline
Percent of "value at Week 8 minus value at baseline" over value at baseline
Mean change in the trough SBP
| Arm | Type | Description |
|---|---|---|
| CI-1038 2.5mg/5mg | ACTIVE_COMPARATOR | - |
| CI-1038 2.5mg/10mg | ACTIVE_COMPARATOR | - |
| CI-1038 5mg/5mg | ACTIVE_COMPARATOR | - |
| CI-1038 5mg/10mg | ACTIVE_COMPARATOR | - |
| Amlodipine 5mg | ACTIVE_COMPARATOR | - |
| Amlodipine 10mg | EXPERIMENTAL | - |
| 1 | EXPERIMENTAL | Amlodipine and Benazepril HCl Capsules 10 mg/20 mg |
| 2 | ACTIVE_COMPARATOR | Lotrel® Capsules 10 mg/20 mg |
| Name | Type | Description |
|---|---|---|
| Amlodipine 2.5mg/Atorvastatin 5mg | DRUG | Single pill combination, dosed once daily for 8 weeks |
| Amlodipine 2.5mg/Atorvastatin 10mg | DRUG | Single pill combination, dosed once daily for 8 weeks |
| Amlodipine 5mg/Atorvastatin 5mg | DRUG | Single pill combination, dosed once daily for 8 weeks |
| Amlodipine 5mg/Atorvastatin 10mg | DRUG | Single pill combination, dosed once daily for 8 weeks |
| Amlodipine | DRUG | Amlodipine 5mg/ day |
| Amlodipine/Atorvastatin | DRUG | - |
| Amlodipine/atorvastatin single pill | DRUG | - |
| Amlodipine and Benazepril HCl Capsules 10 mg/20 mg | DRUG | 10/120mg, single dose fed |
| Lotrel® Capsules 10 mg/20 mg | DRUG | 10/20mg, single dose fed |
Inclusion Criteria: * The out-patient with concurrent hypertension and hyper-LDL-cholesterolemia is a male or female \>=20 to \<80 years of age at Visit 1. * The SBP at Visit 4 (Week -1) and Visit 5 (Week 0) is continuously SBP \>=140 mmHg and \<180 mmHg, * LDL-C \>=140 mg/dL and \<250 mg/dL at Vis...
Top 9 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 5 | PHASE3 | Baxdrostat |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Clazakizumab |
| Alnylam Pharmaceuticals, Inc | ALNY | 2 | PHASE3 | Zilebesiran, ALN-AGT01 RVR |
| Mineralys Therapeutics, Inc. | MLYS | 1 | PHASE3 | lorundrostat |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE2 | QCZ484, HJB647 |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | iloperidone |
| Opus Genetics, Inc. | IRD | 1 | PHASE1 | OPGx-BEST1 |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX340 |
Amlodipine and Benazepril is a fixed dose combination product developed by Viatris Inc. (ticker VTRS). It combines amlodipine, a calcium channel blocker, with benazepril, an ACE inhibitor, in a single oral capsule. The specific presentation referenced here is Amlodipine and Benazepril HCl Capsules 10 mg/20 mg.
Amlodipine and Benazepril targets the calcium channel subunits CACNA1C, CACNA1S, CACNA1D, and CACNA1F. Amlodipine acts as a blocker at these L type calcium channels, while benazepril is an ACE inhibitor. This dual mechanism is intended to lower blood pressure through complementary pathways.
Amlodipine and Benazepril is developed by Viatris Inc., which trades under the ticker VTRS. Viatris is the company associated with the Amlodipine and Benazepril HCl Capsules 10 mg/20 mg presentation described in this reference.
Amlodipine and Benazepril is in Phase 1 development. The single registered trial for this asset is a Phase 1 study, and it has been completed. The program is not currently active, with no ongoing trials listed.
Amlodipine and Benazepril has been studied in one completed Phase 1 trial, NCT00649402, titled Fed Study of Amlodipine and Benazepril HCl Capsules 10 mg/20 mg to Lotrel Capsules 10 mg/20 mg. The trial enrolled 64 healthy adult volunteers in the United States and used an active controlled, randomized design.